Serotonin

Serotonin

SCHEMBL1675866

N.NCCc1c[nH]c2ccc(O)cc12

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 7/20 0.97
HTR2A P28223 7/20 0.97
HTR1A P08908 7/20 0.97
HTR1D P28221 6/20 0.97
HTR1B P28222 4/20 0.97
HTR7 P34969 3/20 0.97
HTR2B P41595 2/20 0.97
CYP2D6 P10635 2/20 0.97
CYP1A2 P05177 2/20 0.97
TSHR P16473 2/20 0.97
HTR5A P47898 2/20 0.97
HTR6 P50406 2/20 0.97
HTR3E A5X5Y0 1/20 0.97
HTR3B O95264 1/20 0.97
CYP3A4 P08684 1/20 0.97
CYP2C9 P11712 1/20 0.97
DRD1 P21728 1/20 0.97
HTR1E P28566 1/20 0.97
HTR1F P30939 1/20 0.97
DRD3 P35462 1/20 0.97

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Serotonin SCHEMBL30057954 0.98 HTR2C (1.00) HTR2CHTR2AHTR1AHTR1DHTR1B
Serotonin SCHEMBL29349412 0.98 HTR2C (1.00) HTR2CHTR2AHTR1AHTR1DHTR1B
Serotonin SCHEMBL1495 0.98 HTR2C (1.00) HTR2CHTR2AHTR1AHTR1DHTR1B
Serotonin SCHEMBL183226 0.98 HTR2C (1.00) HTR2CHTR2AHTR1AHTR1DHTR1B
Serotonin SCHEMBL25341783 0.97 HTR2C (1.00) HTR2CHTR2AHTR1AHTR1DHTR1B
Serotonin SCHEMBL8208967 0.97 HTR2C (1.00) HTR2CHTR2AHTR1AHTR1DHTR1B
Serotonin SCHEMBL29781387 0.97 HTR2C (1.00) HTR2CHTR2AHTR1AHTR1DHTR1B
Serotonin SCHEMBL28576451 0.97 HTR2C (0.97) HTR2CHTR2AHTR1AHTR1DHTR1B
Serotonin SCHEMBL396997 0.97 HTR2C (0.97) HTR2CHTR2AHTR1AHTR1DHTR1B
Serotonin SCHEMBL3091827 0.97 HTR2C (0.97) HTR2CHTR2AHTR1AHTR1DHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1687314-B1 PREPARATION OF 1-AZA-2-OXA-DIBENZO [e,h] AZULENES AND THEIR USE FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS GLAXOSMITHKLINE ZAGREB (HR) 2008-12-24 EP claimed
EP-1684766-B1 USE OF 3-AZA-1-OXA-DIBENZO i e,h /i AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEAS AND DISORDERS GLAXOSMITHKLINE ZAGREB (HR) 2007-06-27 EP claimed
CN-117752734-A New use of liver and kidney tonifying compound traditional Chinese medicine in treatment of fibromyalgia syndrome 安徽中医药大学第一附属医院(安徽省中医院) 2024-03-26 CN disclosed
WO-2024040322-A1 BIOMIMETIC PEPTIDES DERIVED FROM THE FACTOR THYMOSIN-B4, FUNCTIONALIZED WITH 5-HT AND 5-HTP*, DERMOCOSMETIC AND BIOPHARMACEUTICAL COMPOSITIONS CONTAINING THE PEPTIDES AND USES THEREOF NANOCEUTICALS (BR) 2024-02-29 WO disclosed
US-11896600-B2 Composition and method of using eicosanoyl-5-hydroxytryptamide for treating neurodegenerative disorders Vidya Herbs, Inc. (US) 2024-02-13 US disclosed
WO-2023133159-A1 WEARABLE APTAMER FIELD-EFFECT TRANSISTOR SENSING SYSTEM FOR NONINVASIVE CORTISOL MONITORING AND WEARABLE SYSTEM FOR STRESS SENSING THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-07-13 WO disclosed
WO-2023099589-A1 IRAP INHIBITORS FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2023-06-08 WO disclosed
US-20230147744-A1 METHODS TO ENRICH ENTEROENDOCRINE CELLS AND THEIR SUBTYPES IN THE CONTIGUOUS, INTESTINAL MONOLAYER SYSTEMS UNIVERSITY OF WASHINGTON 2023-05-11 US disclosed
US-20230098772-A1 ADVANCED MICROBIOME THERAPEUTICS ENGINEERED TO PRODUCE SEROTONIN IN VIVO THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2023-03-30 US disclosed
EP-4126218-A1 METHODS TO ENRICH ENTEROENDOCRINE CELLS AND THEIR SUBTYPES IN THE CONTIGUOUS, INTESTINAL MONOLAYER SYSTEMS The University of North Carolina at Chapel Hill (US) 2023-02-08 EP disclosed
CN-110041318-B Dopamine D5 receptor agonist and preparation and application thereof 中国科学院上海药物研究所 2022-07-29 CN disclosed
WO-2001013715-A2 ANIMAL MODEL AND USES THEREOF THE BABRAHAM INSTITUTE (GB) 2001-03-01 WO disclosed
WO-2000064935-A1 A NOVEL SEROTONIN-GATED ANION CHANNEL MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2000-11-02 WO disclosed
US-6060642-A TRANSGENIC MICE MODELS FOR GENE FUNCTION, WHEREIN THE TRANSGENIC MICE ARE CHARACTERIZED BY HAVING ALTERED SEROTONIN 5-HT6 RECEPTOR GENE FUNCTION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-05-09 US disclosed
US-5990094-A SEROTONIN N-ACETYLTRANSFERASE INHIBITORS WHICH CAN SERVE AS BIOLOGICAL TOOLS THAT HELP REVEAL BIOLOGICAL FUNCTIONS FOR MELATONIN AND PINEAL SEROTONIN IN VIVO; ACETYL-COA N-ACETYL TRYPTAMINE DERIVATIVES OF GIVEN STRUCTURE THE ROCKEFELLER UNIVERSITY (US) 1999-11-23 US disclosed
WO-1998055141-A9 METHODS AND PRODUCTS FOR INDUCING APOPTOSIS IN NEUROENDOCRINE CELLS WITH MACROPHAGE STIMULATING PROTEIN BRIGHAM & WOMENS HOSPITAL (US) 1999-04-08 WO disclosed
EP-0893950-A1 SELECTIVE TARGET CELL ACTIVATION BY EXPRESSION OF A G PROTEIN-COUPLED RECEPTOR ACTIVATED SUPERIORLY BY SYNTHETIC LIGAND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-02-03 EP disclosed
WO-1998055141-A1 METHODS AND PRODUCTS FOR INDUCING APOPTOSIS IN NEUROENDOCRINE CELLS WITH MACROPHAGE STIMULATING PROTEIN BRIGHAM & WOMEN'S HOSPITAL, INC. (US) 1998-12-10 WO disclosed
WO-1997035478-A1 SELECTIVE TARGET CELL ACTIVATION BY EXPRESSION OF A G PROTEIN-COUPLED RECEPTOR ACTIVATED SUPERIORLY BY SYNTHETIC LIGAND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-10-02 WO disclosed
EP-0165800-A1 Support material for immobilisation of ligands NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1985-12-27 EP disclosed